# IMJUDO

NDC: 0310-4535
Generic name: tremelimumab
Labeler / Manufacturer: AstraZeneca Pharmaceuticals LP
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: INTRAVENOUS
Marketing started: 20221021

FDA application: BLA761289

## Active ingredients

- TREMELIMUMAB: 300 mg/15mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0310-4535"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0310-4535
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6690679c-be2f-4588-a2e4-89fff74dd6be